![CIMZIA[®] is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose for Patients Across the Full Axial Spondyloarthritis Spectrum](/_up/ucb_com_presscenter/images/presscenter_teaser_14.jpg?300)
We are delighted to be taking part at this year’s virtual #WCO-IOF-ESCEO congress, where we are pleased to be working with Prof Gaetano De Ferrari who along with his peers will be discussing the latest developments in osteoporosis and fragility fracture care.
Top of this page
Skip navigation, go straight to the content
Newsroom
•
Overview
Newsroom
Press Release
Social Media
Twitter Feed
Resources
Access our media image selection or contact us for particular requests.
UCB on YouTube
Contact
The UCB media relations team responds to calls and emails from professional journalists only.